tiprankstipranks
Trending News
More News >

CARsgen Therapeutics Reports 2024 Financial Results with Increased Net Loss

Story Highlights

An update from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) is now available.

CARsgen Therapeutics Holdings Ltd. announced its annual results for 2024, reporting a revenue of approximately RMB39.4 million, primarily from its BCMA CAR T-cell product. Despite achieving a gross profit of RMB14.7 million, the company faced a net loss of RMB798 million, an increase from the previous year, attributed to higher net other losses and reduced R&D expenses. The company’s cash reserves decreased to RMB1,479 million, with expectations of maintaining adequate cash flow into 2028.

More about CARsgen Therapeutics Holdings Ltd.

CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on the development of innovative CAR-T cell therapies. The company specializes in autologous BCMA CAR T-cell products, with a market focus on cancer treatment.

YTD Price Performance: 49.19%

Average Trading Volume: 8,523,933

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$7.28B

For a thorough assessment of 2171 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App